Symphony Therapeutics to Debut Uses of Novel LNP Platform at 2024 TechConnect World Innovation Conference June 18, 2024

June 04, 2024 11:12 PM AEST | By EIN Presswire

Google News:

Symphony Therapeutics to Debut Uses of Novel LNP Platform at 2024 TechConnect World Innovation Conference June 18, 2024 — Image source: EIN Presswire

Recent News

CyberQP and Pax8 Accelerate Global Growth Across APAC, ANZ, and North...

Update on Oyu Tolgoi mine plan

Bernstein downgrades CrowdStrike on valuation, sees better upside in P...

U.S. tariffs have been implemented at a faster pace than expected - Da...

Integral BioSystems spinoff Symphony Therapeutics will present drug development utilizing Integral's OcuHeal™ LNP platform

Symphony Therapeutics is poised to transform ophthalmic drug delivery utilizing Integral BioSystems’ fully patented OcuHeal LNP™ platform.”

— Dr. Shikha Barman

BEDFORD, MA, US, June 4, 2024 /EINPresswire.com/ -- Dr. Shikha P. Barman of Symphony Therapeutics will present details of the uses of Symphony's innovative OcuHeal™ LNP technology for therapeutic applications at the 27th Annual TechConnect World Innovation Conference and Expo, Tuesday June 18, 2024 at the Gaylord National Convention Center, National Harbor, Maryland, U.S.A. OcuHeal™ LNP technology has been patented in numerous global jurisdictions, and has been enabled for multiple indications in ophthalmology and dermatology. The presentation, to be presented in Booth# 709, is Abstract submission number 362 entitled: OcuHeal UV-400+ : Ophthalmic, UV-blocking, Anti-oxidant, Preservative-free Nanolipid Eye-drop.

A substantial number of ophthalmic drug products for disorders of the ocular surface are hydrophobic, or sparingly soluble in water, and formulated as suspensions. This results in less than 5% of each eye-drop actually being absorbed by the target tissue. Such formulations typically contain a high concentration of drug to achieve a therapeutic effect. OcuHeal’s nanostructured emulsions are formulated into mucosa-penetrating, tissue absorbed nanoparticles, melting at body temperature to release dissolved drug at the requisite tissue site, allowing much less drug to be administered for equivalent or better therapeutic effect.

Symphony Therapeutics is developing an ophthalmic development pipeline utilizing this technology patented by Integral BioSystems, inviting the exploration of licensing-based collaborations for other potential applications in ophthalmic, dermal or other routes that can benefit from this technology.

Dave Karasic
Integral BioSystems, LLC
+1 617-820-8483
email us here

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.